Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of Relatlimab + Nivolumab + 5-azacytidine in Refractory/Relapsed and Newly Diagnosed Older Acute Myeloid Leukemia
2018-002939-21Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab, nivolumab and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by LMU Klinikum. Primary endpoints: Maximum tolerated dose (MTD) of relatlimab + nivolumab + azacitidine and Dose-limiting toxicities (DLT). Started Oct 2019; status: active.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002939-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002939-21.